CN107096035A - A kind of chitosan/calcium carboxymethylcellulose ionic oxide formation graphene composite material discharges for pH regulating medicines - Google Patents
A kind of chitosan/calcium carboxymethylcellulose ionic oxide formation graphene composite material discharges for pH regulating medicines Download PDFInfo
- Publication number
- CN107096035A CN107096035A CN201710256180.3A CN201710256180A CN107096035A CN 107096035 A CN107096035 A CN 107096035A CN 201710256180 A CN201710256180 A CN 201710256180A CN 107096035 A CN107096035 A CN 107096035A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- graphene oxide
- composite material
- carboxymethyl cellulose
- calcium ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 37
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 239000002131 composite material Substances 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title claims abstract description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 title claims abstract description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 title abstract description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 title abstract description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 title abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 4
- 229910052791 calcium Inorganic materials 0.000 title abstract 4
- 239000011575 calcium Substances 0.000 title abstract 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 25
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 24
- 238000013019 agitation Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 229960002949 fluorouracil Drugs 0.000 claims description 12
- 239000008055 phosphate buffer solution Substances 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000008351 acetate buffer Substances 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 230000001186 cumulative effect Effects 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 230000001934 delay Effects 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000029219 regulation of pH Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Discharged the present invention relates to a kind of chitosan/calcium carboxymethylcellulose ionic oxide formation graphene composite material applied to pH regulating medicines.Comprise the following steps：A kind of chitosan/calcium carboxymethylcellulose ionic oxide formation graphene composite material is prepared, by drug loading on the composite, vitro drug release is regulated and controled with pH.The beneficial effects of the invention are as follows：Chitosan/calcium carboxymethylcellulose ionic oxide formation graphene composite material has excellent pH sensitiveness, and controllable medicine slowly discharges under different pH environment.
Description
Technical field
Regulate and control the present invention relates to a kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material for pH
Insoluble drug release, belongs to biomedicine field.
Technical background
Cancer is one of health threat of current facing mankind, has many patients dead because of cancer every year.There is many
Anticarcinogen is used among the treatment of Cancerous disease, and wherein 5 FU 5 fluorouracil is a kind of medicine for the treatment of cancer, clinically wide
It is general to be used to treat breast cancer, stomach cancer, intestinal cancer and colon cancer.But its half-life period very short only 10~20min, it is therefore desirable to pass through medicine
Thing controlled-release technology come reduce administration number of times and lifting disease therapeuticing effect.
Graphene oxide has larger lamellar structure, big pi bond, oxygen-containing functional group and a preferable biocompatibility, but compared with
Good water solubility limits its application in biomaterial.Natural polysaccharide have preferable biocompatibility, biological non-toxicity and
The advantages such as biodegradability.Wherein chitosan is that have substantial amounts of amino in cation natural polysaccharide, its long-chain, passes through amino
Protonation and deprotonation the chain structure of chitosan can be made to change, cause it that there is pH sensitiveness.Carboxymethyl cellulose
Element is derived by cellulose to be prepared, and carboxymethyl is rich in its backbone.Therefore by chitosan, carboxymethyl cellulose,
Graphene oxide be prepared into composite play the role of in biomedicine field it is critically important.
The content of the invention
The purpose of the present invention is to be to provide a kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite wood
Material is applied to the release of pH regulating medicines.
A kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material of the present invention regulates and controls for pH
Insoluble drug release, comprises the following steps：
A, prepare chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material：By 300mg carboxymethyl celluloses
Plain sodium and 100mg graphene oxide is added in the beaker equipped with 150mL acetate buffer solutions, is kept after magnetic agitation 1h, is added
5mL concentration is 8mg/mL calcium chloride solution, continues magnetic agitation 30min, takes 100mg chitosans to be added to the vinegar equipped with 50mL
In the beaker of acid buffer, after magnetic agitation 1h, the mixed solution of sodium carboxymethylcellulose, graphene oxide and calcium chloride is poured into
In, and adjusted the pH of solution to neutrality using 2wt% sodium hydroxides, natural subsidence, washing three times are simultaneously freezed at -45 DEG C
Dry 24h；
B, prepare chitosan/carboxymethyl cellulose-calcium ion-graphene oxide and carry medicine composite：Weigh 200mg steps
A prepares chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material and is dispersed in 100mL ultra-pure waters, and adds
5 FU 5 fluorouracil, lucifuge magnetic agitation, filtering, washing are simultaneously freeze-dried 24h at -45 DEG C；
C, the chitosan/carboxymethyl cellulose-calcium ion-graphene oxide for taking 15mg steps b to prepare carry medicine composite,
It is placed in bag filter, and bag filter is put in 50mL phosphate buffer solutions keeps magnetic agitation, is 37 DEG C of conditions in temperature
Lower to carry out external pH regulating medicines release, the pH for the phosphate buffer solution that tablets in vitro is used is 1.2,5.5 and 7.4, every
30min takes out 3mL solution from drug release container, while adding the phosphate buffer solution that 3mL newly matches somebody with somebody, uses ultraviolet specrophotometer
The content of 5 FU 5 fluorouracil is determined at 265nm, and calculates the cumulative release percentage of 5 FU 5 fluorouracil.
Further, the pH scopes of acetate buffer solution are 4.5~6.0 in step a.
Further, it is 1~48h that the medicine time is carried in step b.
Further, the concentration of 5 FU 5 fluorouracil is 0.1~10mg/mL in step b.
Further, the concentration of phosphate buffer solution is 0.1~0.5mol/L in step c.
The beneficial effects of the invention are as follows：Chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material has
Excellent pH sensitiveness, controllable medicine slowly discharges under different pH environment.
Brief description of the drawings
This experiment is further illustrated below in conjunction with the accompanying drawings.
Fig. 1 sweeps for chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material Flied emission in embodiment one
Retouch electron microscope.
Fig. 2 is the external pH tune of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material in embodiment two
Control medicament slow release performance figure.
Embodiment
Presently in connection with specific embodiment, the present invention will be further described, following examples be intended to illustrate invention rather than
Limitation of the invention further.
Embodiment one：
Preparing chitosan/carboxymethyl cellulose-calcium ion-graphene oxide load medicine composite includes following step
Suddenly：
(1) 300mg sodium carboxymethylcelluloses and 100mg graphene oxides are added to equipped with 150mL acetate buffer solutions (pH
In=beaker 5.0), keep after magnetic agitation 1h, add the calcium chloride solution that 5mL concentration is 8mg/mL, continue magnetic agitation
30min.Take 100mg chitosans to be added in the beaker equipped with 50mL acetate buffer solutions (pH=5.0), after magnetic agitation 1h, fall
In the mixed solution for entering sodium carboxymethylcellulose, graphene oxide and calcium chloride, and sodium hydroxide (2wt%) is used by solution
PH is adjusted to neutrality.Natural subsidence, washing three times are simultaneously freeze-dried 24h at -45 DEG C.
(2) chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite wood of 200mg steps (1) preparation is weighed
Material is dispersed in 100mL ultra-pure waters, and adds 50mg 5 FU 5 fluorouracil, lucifuge magnetic agitation 24h.Filter, wash and -45
24h is freeze-dried at DEG C.It is as shown in Figure 1 chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material hair
Penetrate scanning electron microscope (SEM) photograph.
Embodiment two：
The lower vitro drug release behavior of pH regulation and control includes following steps：
Chitosan/carboxymethyl cellulose-calcium ion-graphene oxide carries the preparation process and embodiment one of medicine composite
It is identical
(1) preparing 0.1mol/L phosphate buffer solution is used to simulate human body environment, weighs 15mg chitosans/carboxymethyl
Cellulose-calcium ion-graphene oxide carries medicine composite, is placed in bag filter, and bag filter is put into 50mL phosphate
Cushioning liquid keeps magnetic agitation, and external pH regulation and control drug release is carried out under the conditions of temperature is 37 DEG C.The pH of phosphate buffer solution
For 1.2,5.5 and 7.4.
(2) 3mL solution is taken out from drug release container every 30min, while adding the phosphate buffer solution that 3mL newly matches somebody with somebody.Make
The content of 5 FU 5 fluorouracil is determined at 265nm with ultraviolet specrophotometer, and calculates the cumulative release percentage of 5 FU 5 fluorouracil
Number.As shown in Figure 2 with the pH value increase of drug release environment, the cumulative release amount of 5 FU 5 fluorouracil is consequently increased.
Claims (5)
1. a kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material discharges for pH regulating medicines, its
It is characterised by：Step is as follows：
A, prepare chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material：By 300mg sodium carboxymethylcelluloses
It is added in the beaker equipped with 150mL acetate buffer solutions, is kept after magnetic agitation 1h with 100mg graphene oxides, adds 5mL dense
The calcium chloride solution for 8mg/mL is spent, continues magnetic agitation 30min, takes 100mg chitosans to be added to the acetic acid equipped with 50mL and delays
In the beaker of fliud flushing, after magnetic agitation 1h, in the mixed solution for pouring into sodium carboxymethylcellulose, graphene oxide and calcium chloride,
And adjusted the pH of solution to neutrality using 2wt% sodium hydroxides, natural subsidence, washing three times are simultaneously freeze-dried at -45 DEG C
24h；
B, prepare chitosan/carboxymethyl cellulose-calcium ion-graphene oxide and carry medicine composite：Weigh 200mg step a systems
Standby chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material is dispersed in 100mL ultra-pure waters, and adds 5- fluorine
Uracil, lucifuge magnetic agitation, filtering, washing are simultaneously freeze-dried 24h at -45 DEG C；
C, the chitosan/carboxymethyl cellulose-calcium ion-graphene oxide for taking 15mg steps b to prepare carry medicine composite, are placed in
In bag filter, and bag filter is put in 50mL phosphate buffer solutions keeps magnetic agitation, be to enter under the conditions of 37 DEG C in temperature
The external pH regulating medicines release of row, the pH for the phosphate buffer solution that tablets in vitro is used is 1.2,5.5 and 7.4, every 30min
3mL solution is taken out from drug release container, while adding the phosphate buffer solution that 3mL newly matches somebody with somebody, is existed using ultraviolet specrophotometer
The content of 5 FU 5 fluorouracil is determined at 265nm, and calculates the cumulative release percentage of 5 FU 5 fluorouracil.
2. a kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material is used for according to claim 1
PH regulating medicines discharge, it is characterized in that：The pH scopes of acetate buffer solution are 4.5~6.0 in the step a.
3. a kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material is used for according to claim 1
PH regulating medicines discharge, it is characterized in that：It is 1~48h that the medicine time is carried in the step b.
4. a kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material is used for according to claim 1
PH regulating medicines discharge, it is characterized in that：The concentration of 5 FU 5 fluorouracil is 0.1~10mg/mL in the step b.
5. a kind of chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material is used for according to claim 1
PH regulating medicines discharge, it is characterized in that：The concentration of phosphate buffer solution is 0.1~0.5mol/L in the step c.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710256180.3A CN107096035B (en) | 2017-04-19 | 2017-04-19 | Chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material for regulating and controlling pH to regulate and control drug release |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710256180.3A CN107096035B (en) | 2017-04-19 | 2017-04-19 | Chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material for regulating and controlling pH to regulate and control drug release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107096035A true CN107096035A (en) | 2017-08-29 |
| CN107096035B CN107096035B (en) | 2019-12-06 |
Family
ID=59658194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710256180.3A Active CN107096035B (en) | 2017-04-19 | 2017-04-19 | Chitosan/carboxymethyl cellulose-calcium ion-graphene oxide composite material for regulating and controlling pH to regulate and control drug release |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107096035B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103232989A (en) * | 2013-04-23 | 2013-08-07 | 天津工业大学 | Preparation method of alginate hybrid hydrogel film and grafting material of immobilized bio-macromolecule |
| CN104974371A (en) * | 2014-04-11 | 2015-10-14 | 山东大学 | Preparation method of graphene/chitosan porous composite material |
| KR20160038443A (en) * | 2014-09-30 | 2016-04-07 | 한국화학연구원 | Graphene oxide loaded polyelectrolyte complex membrane for separation of alcohol-water mixture and the preparation method thereof |
-
2017
- 2017-04-19 CN CN201710256180.3A patent/CN107096035B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103232989A (en) * | 2013-04-23 | 2013-08-07 | 天津工业大学 | Preparation method of alginate hybrid hydrogel film and grafting material of immobilized bio-macromolecule |
| CN104974371A (en) * | 2014-04-11 | 2015-10-14 | 山东大学 | Preparation method of graphene/chitosan porous composite material |
| KR20160038443A (en) * | 2014-09-30 | 2016-04-07 | 한국화학연구원 | Graphene oxide loaded polyelectrolyte complex membrane for separation of alcohol-water mixture and the preparation method thereof |
Non-Patent Citations (10)
Also Published As
| Publication number | Publication date |
|---|---|
| CN107096035B (en) | 2019-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022105301A1 (en) | Asiaticoside-chitosan-sodium-alginate microsphere, and preparation method therefor and use thereof | |
| CN102224896A (en) | Health food for enhancing human immunity and increasing bone mineral density and preparation method thereof | |
| WO2020113811A1 (en) | Biopolymer nanosphere containing nicotinamide mononucleotide, preparation method therefor and use thereof | |
| CN110496214A (en) | A kind of oyster peptide combinations and preparation method thereof improving male's sexual | |
| CN102406205B (en) | Oyster polysaccharide fruit juice beverage | |
| CN107375221B (en) | Calcium tablet containing vitamin K2 and preparation method thereof | |
| CN108451979B (en) | Lycopene compound preparation with auxiliary treatment effect on prostate cancer and application thereof | |
| CN105873595A (en) | Combination drug for regulating autonomic nervous system, and preparation, product, and application thereof | |
| WO2016045308A1 (en) | Application of oligomeric sodium alginate preparation in pharmaceuticals and health care products and salt products | |
| CN105193707A (en) | Ambroxol hydrochloride oral solution and preparation method thereof | |
| CA3159355A1 (en) | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | |
| CN107536806A (en) | A kind of preparation method of microspheroidal applied to drug sustained release system and chitosan/calcium carbonate with pH responses | |
| CN1823764A (en) | Medicinal composition containing strontium fuminate and vitamin D | |
| CN105166938A (en) | Casein and bone protocalcium compound probiotic preparation | |
| CN107969649A (en) | One kind is replenished the calcium composition and preparation method | |
| CN107096035A (en) | A kind of chitosan/calcium carboxymethylcellulose ionic oxide formation graphene composite material discharges for pH regulating medicines | |
| CN103536623B (en) | Potassium magnesium aspartate composition freeze-dried powder for injection | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| CN109289000A (en) | It is a kind of to treat gynaecological imflammation gel and preparation method thereof | |
| CN104256651A (en) | Composition for improving male sexual function and preparation method and application thereof | |
| CN107668724A (en) | A kind of compound preparation of ammonia sugar chondroitin collagen turmeric and preparation method thereof | |
| CN101327316A (en) | Formulation for treating and preventing acalcerosis | |
| CN113082059A (en) | Composition for preventing and treating osteoporosis and preparation method and application thereof | |
| CN112972409A (en) | Gamithromycin sustained release preparation and preparation method thereof | |
| CN103494201B (en) | Osteoarticular disease care product of L-ascorbyl dipalmitate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240115 Address after: 710000 Factory Building 5, South Zone 1, Hongshengxing Aviation Technology Industrial Park, Dunhua Road, Airport New City, Xixian New District, Xi'an City, Shaanxi Province Patentee after: Xi'an Meinan Biotechnology Co.,Ltd. Address before: Gehu Lake Road Wujin District 213164 Jiangsu city of Changzhou province No. 1 Patentee before: CHANGZHOU University |
|
| TR01 | Transfer of patent right |